Study | Reason for exclusion |
---|---|
Aderka 1986 | A non-randomised retrospective study |
Agliastro 2006 | Comparison of apheresis versus buffy coat platelet transfusions ( abstract) |
Akkök 2007 | Comparison of apheresis versus buffy coat platelet transfusions |
Anderson 1997 | Comparison of apheresis versus buffy coat -derived versus platelet rich plasma -derived platelet products |
Andreu 2009 | Review |
Andrew 1993 | Wrong patient group - premature infants |
Arnold 2004 | Comparison of apheresis versus whole blood -derived platelet transfusions |
Arnold 2006 | Wrong patient group - intensive treatment unit |
Avvisati 2003 | Review |
Bai 2004 | Wrong patient group - solid tumours |
Benjamin 2002 | Review |
Bentley 2000 | Comparison of autologous versus allogeneic platelet transfusions |
Blajchman 2008 | Review |
Blumberg 2002 | Comparison of washed versus standard platelet transfusions |
Blumberg 2004 | Comparison of washed versus standard platelet transfusions |
Blundell 1996 | Comparison of standard versus pathogen inactivated platelets |
Buhrkuhl 2010 | Review |
Callow 2002 | A non-randomised prospective study with historical control |
Cameron 2007 | A non-randomised prospective study |
Carr 1990 | Comparison of ABO-matched versus mismatched platelet products |
Casbard 2004 | Systematic review and wrong patient group |
Chaoui 2005 | Observational prospective study |
Chaurasia 2012 | A non-randomised prospective study |
Cid 2007 | Systematic review of differing platelet transfusion doses |
Corash 2001 | Comparison of intercept platelet components versus standard platelet components |
Couban 2002 | Comparison of plasma reduction and leucodepletion |
de Wildt-Eggen 2000 | Comparison of platelet concentrates in plasma versus additive solution |
Decaudin 2004 | Non-randomised prospective study |
Di Pietro 1998 | Comparison of HLA -matched versus random -donor apheresis platelet components |
Diedrich 2009 | Comparison of platelet products stored 1 - 5 versus 6 - 7 days |
Dumont 2011 | Comparison of buffy coat versus platelet rich plasma platelet concentrates |
Dzik 2004 | Review |
Eder 2007 | Non-randomised observational study |
Elting 2002 | Retrospective analysis - lymphoma and solid tumours |
Elting 2003 | Non-randomised retrospective cohort - lymphoma and solid tumours |
Fanning 1995 | Wrong patient group - gynaecological cancer |
Follea 2004 | Guideline |
Friedmann 2002 | A non-randomised retrospective analysis |
Gajic 2006 | Wrong patient group - intensive treatment unit |
Gerday 2009 | Wrong patient group - neonates |
Gil-Fernandez 1996 | A non-randomised retrospective historical control study (different platelet transfusion thresholds) |
Gmür 1983 | Comparison of single -donor versus pooled platelet products |
Gmür 1991 | A non-randomised prospective cohort observational study (different platelet transfusion thresholds) |
Goodnough 2001 | Fewer than 80% of participants diagnosed with a haematological disorder - different platelet doses |
Goodnough 2002 | Review |
Goodnough 2005 | Review |
Goodrich 2008 | Comparison of pathogen inactivated versus standard apheresis platelets |
Greeno 2007 | A non-randomised prospective observational study (different platelet transfusion thresholds) |
Grossman 1980 | Comparison of prophylactic versus therapeutic platelet transfusions |
Gurkan 2007 | Comparison of apheresis versus pooled platelet products |
Hardan 1994 | A non-randomised observational study, therapeutic platelets only, historical control reported only as an abstract |
Harrup 1999 | Comparison of buffy coat plasma versus T-sol platelet transfusions |
Heal 1993 | Comparison of ABO -compatible versus mismatched platelet transfusions |
Heal 2004 | Review |
Heddle 1994 | Comparison of plasma from platelet concentrates versus platelets |
Heddle 1999 | Comparison of plasma removal versus leucodepletion |
Heddle 2002 | Comparison of plasma removal versus leucodepletion |
Heddle 2003 | Systematic review - methods of assessing bleeding outcome |
Heddle 2005 | Comparison of whole blood -derived platelets stored as a pool versus individually |
Heddle 2007 | Review |
Heddle 2009 | Comparison of a low dose versus standard platelet component dose |
Higby 1974 | Comparison of prophylactic platelets versus platelet poor plasma |
ISRCTN01292427 | Comparison of dynamic light scattering-screened versus unscreened platelets |
ISRCTN49080246 | Comparison of 1 - 5 versus 6 - 7 day -old platelet transfusions |
ISRCTN56366401 | Comparison of different types of platelet component |
Jelic 2006 | Review |
Johansson 2007 | Wrong patient group - ruptured abdominal aortic aneurysm |
Julmy 2009 | Wrong patient group - ruptured abdominal aortic aneurysm |
Kakaiya 1981 | Comparison of apheresis versus pooled platelet concentrates |
Kerkhoffs 2010 | Comparison of standard platelets versus pathogen inactivated platelets versus platelets stored in PAS II media |
Klumpp 1999 | A randomised cross-over study. This study was included within the previous systematic review ; however, due to stricter inclusion/exclusion criteria, this study has now been excluded from the review Only laboratory outcomes were reported. 37% of participants had a non-haematological malignancy (breast cancer) |
Kluter 1996 | Comparison of random -donor platelet components from pooled buffy coats versus apheresis platelet components |
Lapierre 2003 | Comparison of standard apheresis platelet products versus a donor reduction policy |
Lawrence 2001 | A non-randomised retrospective historical control study (different platelet transfusion thresholds) |
Leach 1991 | Comparison of warmed versus standard platelet transfusions |
Lee 1989 | Comparison of ABO -matched versus mismatched platelet transfusions |
Levi 2002 | Review |
Lordkipanidze 2009 | Review |
Lozano 2003 | Review |
Lozano 2010 | Efficacy of older platelet transfusions |
Lozano 2011 | Comparison of pathogen inactivated versus conventional platelet products |
Lu 2011 | Comparison of a low -dose versus standard -dose platelet component |
Martel 2004 | Review |
McCullough 2004 | Comparison of pathogen inactivated versus conventional apheresis platelets |
McNicol 2003 | Review |
Messerschmidt 1988 | Comparison of HLA -matched versus mismatched platelet transfusions |
Mirasol 2010 | Comparison of pathogen inactivated versus conventional platelet products |
Murphy 1982 | Comparison of a prophylactic versus therapeutic platelet transfusion policy |
Murphy 1986 | Comparison of HLA -matched and leucodepleted blood products |
Navarro 1998 | A non-randomised retrospective historical control observational study (different platelet transfusion thresholds) |
NCT00699621 | Wrong patient group - intracerebral haemorrhage |
NCT01615146 | Comparison of a prophylactic versus therapeutic platelet transfusion policy |
Nevo 2007 | A non-randomised retrospective analysis (different platelet thresholds) |
Norol 1998 | A non-randomised prospective comparison ( 3 different doses of platelets) |
Norville 1994 | Comparison of 2 different infusion pumps for platelet transfusions |
Norville 1997 | Comparison of 2 different infusion rates |
Oksanen 1991 | Comparison of pre- versus poststorage leucodepletion of p latelet rich plasma -derived platelet transfusions |
Oksanen 1994 | Comparison of leucodepleted buffy coat -derived platelet transfusions versus historical control |
Paananen 2009 | Non-randomised study (unclear whether prospective or retrospective) |
Pamphilon 1996 | Comparison of buffy coat platelet components, single -donor apheresis non-leucocyte depleted and single - donor apheresis leucocyte-depleted platelet components |
Paramo 2004 | Review |
Poon 2003 | Review |
Qureshi 2007 | Audit of platelet transfusions in the United Kingdom |
Rabinowitz 2010 | Review |
Rayment 2005 | Review |
Razzaghi 2012 | Systematic review of platelet transfusion threshold in people with gastrointestinal bleeding |
Rebulla 2009 | Comparison of pathogen inactivated versus standard platelet components |
Reed 1986 | Wrong patient group - massive transfusion |
Roberts 2003 | Review |
Roy 1973 | Comparison of different platelet component doses |
Sagmeister 1999 | A non-randomised retrospective study (aplastic anaemia) |
Sakakura 2003 | Review |
Samama 2005 | Guideline |
Schiffer 1983 | Comparison of leucodepleted versus standard platelet concentrates |
Sensebe 2004 | Comparison of different platelet component doses |
Shanwell 1992 | Comparison of fresh versus stored platelets |
Shehata 2009 | Systematic review - ABO -identical versus non-identical platelet transfusions |
Shen 2007 | Review |
Singer 1988 | Single -donor HLA -matched versus random -donor platelets |
Sintnicolaas 1981 | Comparison of single -donor and multiple -donor platelet components |
Sintnicolaas 1982 | Comparison of a prophylactic versus therapeutic platelet transfusion policy |
Sintnicolaas 1995 | Comparison of leucocyte depleted versus standard platelets |
Slichter 1998 | Comparison of apheresis versus pooled platelet components |
Slichter 2004 | Review |
Slichter 2006 | Comparison of pathogen inactivated versus conventional apheresis platelets |
Slichter 2007 | Review |
Slichter 2010 | Comparison of different platelet component doses |
Slichter 2012 | Review |
Solomon 1978 | Comparison of a prophylactic versus therapeutic platelet transfusion policy |
Sosa 2003 | Review |
Spiess 2004 | Wrong patient group - cardiac |
Stanworth 2013 | Comparison of a prophylactic versus therapeutic platelet transfusion policy |
Steffens 2002 | Comparison of different platelet component doses |
Strauss 2004 | Review |
Strauss 2005 | Review |
Strindberg 1996 | Comparison of apheresis versus buffy coat platelet products |
Sweeney 2000 | Comparison of pre-storage leucodepleted versus bedside leucodepleted platelets |
Tinmouth 2003 | Review |
Tinmouth 2004 | Comparison of low -dose platelet components versus standard -dose platelet components |
Tosetto 2009 | Guideline |
TRAP 1997 | Comparison of standard pooled platelet product versus irradiated pooled platelet product versus leucodepleted pooled platelet product versus apheresis platelet product |
Vadhan-Raj 2002 | Wrong patient group - gynaecological malignancy |
Van Marwijk 1991 | Comparison of leucodepleted platelet products prepared by filtration or centrifugation |
van Rhenen 2003 | Comparison of pathogen inactivated versus standard buffy coat -derived platelet transfusions |
Velik-Salchner 2007 | Non-human study |
Verma 2008 | A non-randomised observational study |
Wandt 1998 | A non-randomised prospective cohort study (not randomised at the participant level) |
Wandt 2005 | A non-randomised prospective study with an historical case control (therapeutic versus prophylactic platelet transfusions) |
Wandt 2006 | A non-randomised prospective study with an historical case control (therapeutic versus prophylactic platelet transfusions) |
Wandt 2010 | Review |
Wandt 2012 | Comparison of a prophylactic versus therapeutic platelet transfusion policy |
Wang 2002 | A comparison of acetaminophen and diphenhydramine versus placebo as premedication for platelet transfusions |
Wang 2005 | Review |
Weigand 2009 | Prospective observational study |
Williamson 1994 | Comparison of standard versus bedside leucodepleted platelet products |
Woodard 2002 | Review |
Zahur 2002 | Prospective observational study |
Zeller 2014 | Review |
Zhao 2002 | Comparison of leucodepleted versus standard platelet transfusions |
Zumberg 2002 | This study was included within the previous systematic review ; however, due to stricter inclusion/exclusion criteria, this study has now been excluded from the review 31% of participants had a non-haematological malignancy (breast cancer) |
HLA = human leukocyte antigen